Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 13 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 12 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

13Total
P 1 (12)
P 2 (1)

Trial Status

Completed12
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT06957691Phase 2Recruiting

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT05071729Phase 1CompletedPrimary

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

NCT06219902Phase 1CompletedPrimary

A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women

NCT04845841Phase 1CompletedPrimary

Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body

NCT04889287Phase 1CompletedPrimary

A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants

NCT05481528Phase 1CompletedPrimary

A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants

NCT05471817Phase 1CompletedPrimary

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

NCT05381142Phase 1CompletedPrimary

A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years

NCT05351892Phase 1CompletedPrimary

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

NCT04981431Phase 1CompletedPrimary

A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults

NCT04903821Phase 1CompletedPrimary

A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants

NCT05061563Phase 1CompletedPrimary

A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults

NCT05028608Phase 1CompletedPrimary

A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.

Showing all 13 trials

Research Network

Activity Timeline